Document is current
Any future updates will be listed below
-
Authors
Alexander, Laith http://orcid.org/0000-0003-1297-6548
Hawkins, Peter C. T. http://orcid.org/0000-0002-2256-1648
Evans, Jennifer W.
Mehta, Mitul A. http://orcid.org/0000-0003-1152-5323
Zarate, Carlos A. Jr
-
Funding
Funding for this research was provided by:
DH | National Institute for Health Research (ACF-2022-17-016, CRF-2016-10023)
RCUK | Medical Research Council (MR/R005885/1, MR/S003444/1)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIAMH002857, NCT00088699, 04-M-0222)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 28 April 2023
Revised: 14 November 2023
Accepted: 17 November 2023
First Online: 1 December 2023
Competing interests
: CAZ is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2 R,6 R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2 R,6 R)-hydroxynorketamine and (2 S,6 S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.
